行情

BVXV

BVXV

BiondVax
NASDAQ

实时行情|Nasdaq Last Sale

8.29
+1.36
+19.62%
休市 16:00 12/13 EST
开盘
7.00
昨收
6.93
最高
8.40
最低
6.99
成交量
10.67万
成交额
--
52周最高
8.40
52周最低
3.510
市值
1,043.79万
市盈率(TTM)
-80.5637
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BVXV 新闻

  • BVXV: Cohort 2 of Pivotal Phase 3 Universal Influenza Vaccine Trial Fully Enrolled
  • Zacks Small Cap Research.12/04 13:25
  • BiondVax Pharmaceuticals Q3 Opex $5.4M, R&D Expenses $4.6M
  • Benzinga.11/26 12:06
  • BiondVax Announces Third Quarter 2019 Financial Results and Business Update
  • PR Newswire.11/26 12:00
  • Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial
  • PR Newswire.11/18 12:15

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

BVXV 简况

BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
展开

Webull提供Biondvax Pharmaceuticals Ltd - ADR的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。